{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.3","upperLimit":"50.3","value":"41.6"}]}],"title":"10^(-4) Sensitivity"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.6","upperLimit":"49.6","value":"40.9"}]}],"title":"10^(-5) Sensitivity"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.8","upperLimit":"32.9","value":"24.8"}]}],"title":"10^(-6) Sensitivity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"description":"Percentage of participants who achieved ≥ VGPR and MRD negative status at a sensitivity of 10-⁵ at any time point within 3 months prior to achieving at least VGPR until the time of PD/death.\n\nMRD in the bone marrow will be measured using both next generation sequencing (NGS) techniques measuring immunoglobulin gene rearrangements of the malignant clone.\n\nMRD will be reported with a sensitivity of 10-⁴, 10-⁵, and 10-⁶ nucleated cells. The primary analysis for MRD negative response will use the sensitivity of 10-⁵.\n\nMRD = Minimal Residual Disease PD = Progressive Disease VGPR = Very good partial response.","dispersionType":"95% Confidence Interval","groups":[{"description":"BB2121","id":"OG000","title":"BB2121"}],"paramType":"NUMBER","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"From screening to the end of follow up (Approximately 5 years and 2 months)","title":"Percentage of Participants Who Achieved >= VGPR and MRD Negative Status","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}